Original data.xlsx

Previous studies indicate that exogenous use of glucocorticoid (GC) affects immune checkpoint inhibitor (ICI) efficacy. However, there is a paucity of clinical data evaluating the direct impact of endogenous GC on the efficacy for cancer patients with immune checkpoint blockade.

既往研究显示，外源性使用糖皮质激素（glucocorticoid, GC）会影响免疫检查点抑制剂（immune checkpoint inhibitor, ICI）的疗效。然而目前尚缺乏临床数据，用以评估内源性糖皮质激素对接受免疫检查点阻断治疗的癌症患者疗效的直接影响。